San Diego’s ReVision Therapeutics got an encouraging reception over the weekend at a joint meeting in Chicago of the American Academy of Opthalmology and the Middle East-Africa Council of Opthalmology.
Researchers led by Dr. Jason Slakter of the New York University School of Medicine presented results from a mid-stage clinical trial of an experimental drug for treating the “dry” form of age-related macular degeneration (AMD), according to a statement released by the American Academy of Opthalmology. The results show that dry AMD patients at risk of progressing to a more serious form known as “wet” AMD decreased almost two-fold among the patients who took fenretinide, a synthetic derivative of vitamin A.
Slakter also reported that retinal lesion growth was reduced in the fenretinide group. As we reported in August, ReVision has been developing fenretinide as a treatment for dry AMD. The company is planning a late-stage clinical trial to begin in 2011.